A carregar...
Publicação
Pfizer after the covid-19: new opportunity or substantial concentration risk
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 644.95 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
The Equity Research report intends to introduce investors with key insights regarding the stock performance and intrinsic value of Pfizer. Covid-19 pandemic brought new opportunities, as well as new challenges and risks that need to be analyzed to provide a conclusion on which effect prevails and outweighs the other. The full spectrum, from industry analysis and trends to peer comparison represent a value-added approach to the company’s specific data. In the end, the valuation suggests a buy recommendation with Pfizer stock being priced at $56.08 per share by 31 December 2022, representing a 16% annualized shareholder return, including capital gains and dividend payment.
Descrição
Palavras-chave
Valuation M&A Finance Technological innovation Covid-19 Pharma Equity research Wacc Pfizer